Inspire Medical Investors Face Monday Deadline in Class Action Over Inspire V Rollout

Plaintiffs say Inspire overstated Inspire V's readiness, linking hidden billing issues to a sharp guidance cut.

Overview

Investors have until January 5, 2026 to seek appointment as lead plaintiff in the securities case against Inspire Medical Systems.
The suit, pending in the U.S. District Court for the District of Minnesota, covers purchases from August 6, 2024 through August 4, 2025 and includes the caption City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., No. 0:25-cv-04247.
Filings allege the company misled investors about demand and operational readiness for the Inspire V device, citing incomplete training and onboarding, missing IT processes, and reimbursement obstacles.
Notices highlight that Medicare CPT coding existed but claims-processing software updates did not take effect until July 1, 2025, which delayed billing and coincided with excess Inspire IV inventory weighing on demand.
After the August 4, 2025 disclosure, the company cut 2025 earnings guidance by over 80% and shares fell about 32% in a day, a $42.04 drop that erased roughly $1.2 billion in market value.